Graft vs Host Disease: all 815 studies

Page 2 of 9. Open to participants first (138), then studies with results posted, then the rest; newest registration first within each.

• Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)RecruitingNCT05531786Phase 1/2
• The Association of Microbiota Composition With cGVHD After Allo-HSCTRecruitingNCT05355675
• MORPHEE : Mechanisms of Cell Death Induced by Extracorporeal PhotochemotherapyRecruitingNCT05333367Not applicable
• Post-Transplant Cyclophosphamide, Bortezomib and Abatacept for the Prevention of Graft-versus-Host-Disease (GvHD)RecruitingNCT05289167Phase 1/2
• A Prospective, Open Label, Dose-escalation, SAD/MAD, Multicenter, 24weeks, Phase I/IIa Clinical Trial to Evaluate the Safety, Tolerability and Pharmacodynamics of Investigational Product (VM-001) in Patients With Graft-versus-host Disease(GvHD)Not yet recruitingNCT05276076Phase 1/2
• Impact of Exercise on the Complications of Corticosteroids in Patients With GVHD: the RESTART TrialRecruitingNCT05236062Not applicable
• oGVHD After Bone Marrow Transplantation: a Territory-wide CohortRecruitingNCT05170347
• Evaluation of GvHD Damage on Medullary Mesenchymal Stem CellsRecruitingNCT05167188
• Donor Regulatory T-cells for cGVHD in Patients Who do Not Obtain Complete Remission With RuxolitinibRecruitingNCT05095649Phase 2
• HBOT in the Treatment and Prevention of aGVHDRecruitingNCT05078073Not applicable
• Early Access Program With Inolimomab in Steroid-refractory Acute Graft Versus Host DiseaseAvailableNCT05047328
• Prospective Interventional Study Exploring the Microbiota Recolonization in SR-GvHD Patients Receiving MaaT013RecruitingNCT05017688Not applicable
• A Study of Jaktinib for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease.Not yet recruitingNCT04971551Phase 2
• Faecal Microbiota Transplantation After Allogeneic Stem Cell TransplantationRecruitingNCT04935684Phase 2
• PTCY Plus uhCG/EGF for Graft Versus Host Disease ProphylaxisRecruitingNCT04886726Phase 1
• ASC930 in Patients With Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)Not yet recruitingNCT04883918Phase 2
• Early Access Program With MaaT013 in Steroid-refractory Acute Gastrointestinal Graft Versus Host DiseaseAvailableNCT04768907
• Efficacy and Safety of Auto-FMT in Preventing aGVHDRecruitingNCT04745221Not applicable
• A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)RecruitingNCT04710576Phase 2Results posted
• IS-free Treg HaploHCTRecruitingNCT04678401Phase 1
• Relationship Between "FODMAPs" and "GVHD"RecruitingNCT04660487
• GVHD Prophylaxis With Methotrexate in Haploidentical HCT Using Posttransplant CyclophosphamideRecruitingNCT04622956Phase 1/2
• Extended vs Short-term Abatacept Dosing for Graft Versus Host Disease ProphylaxisRecruitingNCT04380740Phase 2
• Biomarker Verification in Pediatric Chronic GvHD: ABLE 2.0 / PTCTC GVH 1901 StudyRecruitingNCT04372524
• A Feasibility Study Using CLINIMACS® for Alpha/Beta T-Cell Depletion in Stem Cell TransplantRecruitingNCT04337515Not applicable
• Safety and Efficacy of Fecal Microbiota TransplantationRecruitingNCT04014413Not applicable
• Post Transplant Cyclophosphamide in Matched Unrelated Donor Stem Cell Transplantation for Hematological MalignanciesRecruitingNCT03818334Phase 2/3
• Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant CyclophosphamideRecruitingNCT03533816Phase 1
• Precision Diagnostics in Inflammatory Bowel Disease, Cellular Therapy and Transplantation (The PREDICT Trial)Enrolling by invitationNCT03369353
• Anti T-lymphocyte Immunoglobulin With Post Transplant Cyclophosphamide to Prevent GVHD Post Allogeneic TransplantationRecruitingNCT03357159Phase 2
• The Effect of Human Leukocyte Antigen Macthing on Guiding Tacrolimus Regimen After Liver TransplantationNot yet recruitingNCT03147157Not applicable
• Therapeutic Effects of Hydrogen on Steroid-refractory/or Steroid-dependent cGVHDRecruitingNCT02918188Phase 2
• Comparative Autoantibody and Immunologic Cell Marker StudyEnrolling by invitationNCT02422875
• A Study Using White Blood Cells From Healthy Donors To Treat Solid CancersEnrolling by invitationNCT00900497Phase 1/2
• Mesenchymal Stem Cell Infusion as Treatment for Steroid-Resistant Acute Graft Versus Host Disease (GVHD) or Poor Graft FunctionRecruitingNCT00603330Phase 2
• Evaluation of Patients With Immune Function AbnormalitiesRecruitingNCT00128973
• Long-term Evaluation and Follow-up Care of Patients Treated With Stem Cell TransplantsRecruitingNCT00106925
• Improved Methods of Cell Selection for Bone Marrow Transplant AlternativesRecruitingNCT00001529
• A Study to Assess the Safety and Pharmacokinetics of GDC-8264 in Combination With Standard of Care in Participants With Acute Graft-Versus-Host Disease (aGVHD)CompletedNCT05673876Phase 1Results posted
• ImmunoCARE: Rapid, Accurate COVID Testing to Reduce Hospitalization of Immunocompromised IndividualsTerminatedNCT05655546Not applicableResults posted
• Using Fostamatinib to Treat Post-Hematopoietic Stem Cell Transplant Immune-mediated CytopeniasTerminatedNCT05502783Phase 2Results posted
• Proof-of-concept Trial of Apraglutide in Acute Graft Versus Host Disease (aGVHD)TerminatedNCT05415410Phase 2Results posted
• Extended Treatment and Follow-up of Subjects Treated With Belumosudil in Study KD025-208 or Study KD025-213CompletedNCT05305989Phase 2Results posted
• A Study to Compare T-Guard vs Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-vs-Host Disease (BMT CTN 2002)TerminatedNCT04934670Phase 3Results posted
• Efficacy and Safety of BN101 in Subjects With Chronic Graft Versus Host Disease (cGVHD)CompletedNCT04930562Phase 2Results posted
• Novel BET Inhibitor PLX51107 for Steroid-Refractory Acute GVHDTerminatedNCT04910152Phase 1/2Results posted
• Dexamethasone Solution and Dexamethasone in Mucolox™CompletedNCT04540133Phase 2Results posted
• Studying Changes in Physical Function Measures in Stem Cell Transplant Patients at Risk for Steroid MyopathyTerminatedNCT04521777Not applicableResults posted
• Cyclophosphamide, Abatacept, and Tacrolimus for GvHD PreventionCompletedNCT04503616Phase 1/2Results posted
• Itacitinib (INCB039110) and Extracorporeal Photopheresis (ECP) for First-Line Treatment in Chronic GVHDTerminatedNCT04446182Phase 2Results posted
• Ibrutinib and Rituxan for Chronic GVHDTerminatedNCT04235036Phase 2Results posted
• A Study of Itacitinib for the Treatment of Chronic Graft Versus Host Disease (cGVHD)TerminatedNCT04200365Phase 2Results posted
• Treatment of GVHD in Hematopoietic Stem Cell Transplant (HSCT) Recipients Using AAT Plus Corticosteroids (CS) Compared With Corticosteroids AloneCompletedNCT04167514Phase 3Results posted
• T-Guard as Treatment for Steroid Refractory Acute GVHD (BMT CTN 1802)TerminatedNCT04128319Phase 3Results posted
• Tildrakizumab for Prevention of Acute Graft-Versus-Host DiseaseCompletedNCT04112810Phase 2Results posted
• Glasdegib for Chronic Graft-Versus-Host DiseaseTerminatedNCT04111497Phase 1/2Results posted
• Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005)TerminatedNCT04095858Phase 3Results posted
• RGI-2001 for the Prevention of Acute Graft-vs-Host Disease in Subjects Following Allogeneic Hematopoietic Stem Cell TransplantationCompletedNCT04014790Phase 2Results posted
• Treatment Safety and Efficacy of Pro-ocular™ 1% for Chronic Ocular Graft Following Allogeneic HSCT.CompletedNCT03990051Phase 2Results posted
• Itacitinib for Low Risk GVHDCompletedNCT03846479Phase 2Results posted
• Activity, Safety and Pharmacokinetics in Pediatric Subjects With Moderate and Severe Chronic Graft vs. Host Disease After Allogeneic Stem Cell TransplantCompletedNCT03774082Phase 2Results posted
• A Study to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity of EQ001 in Subjects With aGVHDCompletedNCT03763318Phase 1/2Results posted
• Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell TransplantationCompletedNCT03755414Phase 1Results posted
• Ex Vivo TCR αβ T Cell Depletion for Graft-Versus-Host Disease Prophylaxis in Mismatched Donor Peripheral Blood Stem Cell Transplantation for Hematologic MalignanciesTerminatedNCT03717480Phase 2Results posted
• Ibrutinib Plus Rituximab for cGVHD Following Allo-SCTTerminatedNCT03689894Phase 1/2Results posted
• Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell TransplantationCompletedNCT03680092Phase 2Results posted
• Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus Host Disease (aGVHD) in Participants Undergoing Allogeneic Hematopoietic Stem Cell (Allo-HSCT) TransplantationCompletedNCT03657160Phase 3Results posted
• Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic TherapyTerminatedNCT03640481Phase 2Results posted
• Study of Ruxolitinib in Sclerotic Chronic Graft-Versus-Host Disease After Failure of Systemic GlucocorticoidsCompletedNCT03616184Phase 2Results posted
• Study of Brimonidine Tartrate Nanoemulsion Eye Drops in Patients With Ocular Graft-vs-Host DiseaseTerminatedNCT03591874Phase 3Results posted
• GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host DiseaseTerminatedNCT03584516Phase 2/3Results posted
• Study of Pharmacokinetics, Activity and Safety of Ruxolitinib in Pediatric Patients With Grade II-IV Acute Graft vs. Host DiseaseCompletedNCT03491215Phase 1/2Results posted
• A Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Steroid Dependent/Refractory Chronic Graft Versus Host Disease (cGVHD)CompletedNCT03474679Phase 3Results posted
• A Proof of Concept Pilot Trial of Alpha-1-Antitrypsin for Pre-Emption Of Steroid-Refractory Acute GVHDCompletedNCT03459040Phase 2Results posted
• Safety and Efficacy of Efavaleukin Alfa in Subjects With Steroid Refractory Chronic Graft Versus Host DiseaseTerminatedNCT03422627Phase 1/2Results posted
• Nutrition and Outcomes of Hematopoietic Cell Transplantation (HCT)CompletedNCT03419078Results posted
• Topical Fibrinogen-Depleted Human Platelet Lysate in Patients With Dry Eye Secondary to Graft vs. Host DiseaseCompletedNCT03414645Phase 1/2Results posted
• Topical Ruxolitinib for Cutaneous Chronic Graft Versus Host Disease (cGVHD)TerminatedNCT03395340Phase 2Results posted
• Detection of Graft Versus Host Disease With [18F]F-AraGCompletedNCT03367962Phase 1Results posted
• An Open-Label Study of Defibrotide for the Prevention of Acute Graft-versus-Host-Disease (AGvHD)CompletedNCT03339297Phase 2Results posted
• Study for the Treatment of Ocular Chronic Graft-Versus-Host Disease (GVHD) With Amniotic Fluid Eye Drops (AFED)CompletedNCT03298815Phase 1/2Results posted
• Belimumab for Prevention of Chronic Graft-versus-Host Disease Following Allogeneic Hematopoietic Cell TransplantationCompletedNCT03207958Phase 1Results posted
• Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell TransplantActive, not recruitingNCT03192397Phase 1/2Results posted
• GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host DiseaseCompletedNCT03139604Phase 3Results posted
• High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell TransplantCompletedNCT03128359Phase 2Results posted
• A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)CompletedNCT03112603Phase 3Results posted
• Study of Ixazomib to Prevent Recurrent or Late Acute and Chronic Graft-versus-Host Disease 1-year After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic MalignanciesCompletedNCT03082677Phase 2Results posted
• Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell DiseaseActive, not recruitingNCT03077542Phase 1/2Results posted
• Extracorporeal Photopheresis and Low Dose Aldesleukin in Treating Patients With Steroid Refractory Chronic Graft-Versus-Host DiseaseCompletedNCT03007238Phase 2Results posted
• Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood CancerTerminatedNCT02999854Phase 3Results posted
• A Dose-Finding Study of Vedolizumab for Treatment of Steroid-Refractory Acute Intestinal Graft-Versus-Host Disease (GvHD) in Participants Who Have Undergone Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT)TerminatedNCT02993783Phase 2Results posted
• Brimonidine Eye Drops for Treatment of Ocular Graft-vs-Host Disease (oGVHD)TerminatedNCT02975557Phase 1/2Results posted
• Treatment of Chronic Graft Versus Host Disease With Arsenic TrioxideCompletedNCT02966301Phase 2Results posted
• Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Participants With New Onset Chronic Graft Versus Host Disease (cGVHD)CompletedNCT02959944Phase 3Results posted
• A Phase 2/3 Study of GLASSIA for the Treatment of Acute GvHDTerminatedNCT02956122Phase 2/3Results posted
• A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1)CompletedNCT02953678Phase 2Results posted
• Safety and Performance Study of the ARGOS-IO System in Patients Undergoing Boston Keratoprosthesis ImplantationCompletedNCT02945176Not applicableResults posted
• Safety and Efficacy of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell TransplantationCompletedNCT02913261Phase 3Results posted
• A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune SuppressionCompletedNCT02891603Phase 1/2Results posted
• Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant PatientsTerminatedNCT02877082Phase 2Results posted

← Graft vs Host Disease overview